Grand Challenges in Global Health

Last updated

The Grand Challenges in Global Health (GCGH) is a research initiative launched by the Bill & Melinda Gates Foundation [1] in search of solutions to health problems in the developing world. Fifteen challenges are categorized in groups among seven stated goals plus an eighth group for family health. The disciplines involved include immunology, microbiology, genetics, molecular biology and cellular biology, entomology, agricultural sciences, clinical sciences, epidemiology, population and behavioral sciences, ecology, and evolutionary biology.

Contents

The Grand Challenges

Goal 1: Improve Vaccines

Potential benefits of this challenge include increased effectiveness of immunization, decreased cost of immunization systems, and decreased deaths in early childhood. One project to combat this challenge that is currently underway is the development of a live recombinant attenuated salmonella anti pneumococcal vaccine for newborns, which is being investigated by Dr. Roy Curtiss III at Arizona State University.
Potential benefits include increased efficacy of immunization systems as well as reduced cost of vaccine delivery. Dr. Abraham L. Sonenschein and his team at Tufts University School of Medicine are currently working to develop childhood vaccines for diphtheria, tetanus, and pertussis that can endure a wide range of temperatures with the encapsulation of heat-resistant bacterial spores.
Potential benefits include improved access and compliance and the avoidance of infection from the re-use of needles. Dr. James R. Baker and a team at the University of Michigan are working on a way of preparing vaccines that can be given as nasal drops, eliminating the need for preservatives or refrigeration.

Goal 2: Create New Vaccines

The priority areas for this challenge are viruses refractory to vaccine development, pathogenic bacteria, and complex pathogens such as protozoa and fungi. Dr. Hongkui Deng of Peking University in China is currently working with his colleagues to create mouse models with immune systems and livers that are similar enough to humans to allow testing of potential HIV and HCV vaccines.
The priority areas for this challenge involve HIV and malaria. Dr. Ralph Steinman and his team are currently developing vaccines that stimulate the immune system’s dendritic cells, which are known to help protect against infectious diseases.
A potential benefit of this challenge is the establishment of new diagnostic and prognostic tools for assessing public health. Dr. Patrick E. Duffy’s team at the Seattle Biomedical Research Institute is currently attempting to identify the antibodies and other immunological responses that help protect children from death due to malaria.

Goal 3: Control Insect Vectors

The priority areas for this challenge include malaria, dengue, and other tropical arboviral diseases. Dr. Scott O’Neill of the University of Queensland in Australia is attempting to modify mosquito population age structure in order to eliminate dengue transmission.
The hope with this challenge is that this challenge will effectively disrupt the diseases transmission cycle. At Virginia Tech University, Dr. Jeffery Bloomquist and a team are using molecular modeling and a new chemical synthesis method known as “click chemistry” to produce insecticides targeted to the primary malaria vector mosquitoes, Anopheles gambiae .

Goal 4: Improve Nutrition

To improve nutrition, this grand challenge focuses on iron, zinc, and selenium deficiencies. At Ohio State University, Dr. Richard Sayre is leading a team of scientists to create nutritious cassava for sub-Saharan Africa.

Goal 5: Limit Drug Resistance

This challenge focuses on TB, Malaria, and HIV. Potential benefits include reduced treatment failures and simple treatment regimens. Dr. Brett Finlay and a team at the University of British Columbia are investigating new therapeutics that boost innate immunity to treat infectious diseases.

Goal 6: Cure Infection

This challenge focuses on HIV, HBV, Herpes, TB, Schistosomiasis, and Toxoplasmosis. Dr. Douglas Young of the Imperial College in London is leading researchers from the U.K, U.S., Singapore, Korea, and Mexico to further expose the biology of latency and then develop drugs against latent TB.
This challenge focuses on similar priority areas as Challenge #11, and Dr. Robert Garcea and a group of researchers from the University of Colorado School of Medicine are working to identify the best protein candidate for a therapeutic vaccine that will target HPV infection.

Goal 7: Measure Health Status

Potential benefits include a standardized global system for assessing the status of population health as well as accurate assessment of injury, disease prevalence, and incidence. Dr. Christopher Murray and international investigators are working to develop ways to assess and measure mortality.
A potential benefit of this challenge is the rapid detection and diagnoses of disease exposure. At Northwestern University, Dr. David Kelso’s team is trying to develop rapid and affordable point-of-care systems. [2]

Two additional challenges for family health were announced in 2011.

A potential benefit of this challenge might lead to new methods of aiding the development of prevention of intrauterine growth restriction (IUGR), stunting, and wasting of newborns and infants in the developing world. [3]
Potential benefits of this initiative could lead to low-cost technologies that reduce the global problem of prematurity.

History

In January 2003, Bill Gates first announced the Grand Challenges in Global Health at the World Economic Forum in Davos, Switzerland. In partnership with the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation (BMFG) granted $200 million to the Foundation for the National Institutes of Health (FNIH). [1] [4] The goal behind the initiative was to fund research to advance the fight against disease that disproportionately affects people in the world's poorest countries. At this time the scientific board's responsibilities were outlined: to identify scientific or technological innovations that have a global impact or show potential for feasibility.[ citation needed ]

In May 2003, the scientific board publicly advertised for ideas. Over a thousand suggestions from scientists and institutions in 75 countries were submitted by July. The scientific board met to further discuss these proposals, which were presented orally with a statement of the problem, descriptions of obstacles to progress, the challenge itself, and a discussion of potential benefits and priority areas for study and application. The following questions raised during the meetings reflect the difficulty in defining these Grand Challenges:[ citation needed ]

In October 2003, the scientific board announced fourteen Grand Challenges.

In August 2004, the evaluation of letters from around the world led to over 400 full proposals. Experts assessed proposals and the Executive Committee of the scientific board and staff members from FNIH and BMGF reviewed the projects to move into the negotiations for grants.

In May 2005, The Bill & Melinda Gates Foundation gave an additional $250 million to fund research for the initiative, bringing the foundation's commitment to $450 million. [6]

In June 2005, the initiative announced grants for 43 new projects, attracting international partners.

Grants for challenges 15 and 16 (in family health) were awarded in 2012.

In February 2015, GCGH and the Global Health Innovative Technology Fund (GHIT) partnered to launch Target Research Platform to invest up to ¥100 million (US$1 million) for early stage development and approximately ¥200 million (US$2 million) in Grand Challenges grant investments per year. Successful projects will then move into GHIT's regular investment program. [7]

Explorations

Launched in 2008, Grand Challenges Explorations, promotes invention in global health research. As of October 2022, the foundation has awarded 3622 grants to researchers in 117 different countries. [8] Some grantees are pursuing radioactivity to kill infected cells, others are trying to develop a waterless toilet that is cost efficient as well as environmentally productive. [9]

The Explorations grant initiative requires two short page applications but no preliminary data. Applications are submitted online. Initial grants of $100,000 are awarded two times a year. Successful projects have the opportunity to receive a follow-on grant of up to $1 million and could eventually evolve into Grand Challenges project. [10]

Ethical, social, and cultural issues

The key challenge associated with such large-scale research projects called for by the initiative is the addressing of ethical, social, and cultural (ESC) issues related to the Grand Challenges. Dr. Peter A. Singer and Dr. James Lavery and a team of colleagues are employing projects to address these barriers, but for the GCGH initiative to be successful, compliance and collaboration with this concept is absolutely critical. [2]

Project goal

The Ethical, Social, and Cultural Program of the Grand Challenges in Global Health, launched in 2005, is targeted to address the ethical, social, and cultural issues that may arise as a result of the initiative - either in the development of the research itself, or in the implementation of knowledge and technology by the communities in need. The GCGH ESC program is the first significant science project concentrated entirely on ESC issues linked to the developing world. [6] ESC issues can have a series of consequences that involve new technologies and approaches: rejection of safety precautions or genetically modified foods, for example, because of culture sensitivity or perceived health, environmental, or economic risks. The ESC program assumes that science and technology are essential to global health development, but the appropriate development of this technology requires attention to the accompanying ethical, social and cultural issues. The program aims to link ESC activities with the research projects and to include voices from the developing world within these projects. Its two main goals are (1) to provide an advisory service for GCGH projects and (2) to create a research program to facilitate appropriate adoption in the long-term.[ clarification needed ] The Bill & Melinda Gates Foundation granted money[ specify ] in November 2005 for the program to be carried out. The program is described and discussed at length in a series of four articles published in PLoS Medicine. [11]

In defining ESC issues, the program's creators underwent a process of document analysis, group discussions with investigators and program staff, and interviews with experts from the developing world. The findings include thirteen issues that include: community engagement, public engagement, cultural acceptability, gender, post-trail obligations/benefit sharing, collaboration, the involvement of civil society organizations, affordability, accessibility, regulatory issues, collection, management, and storage of tissue samples, corruption and poor governance, and unintended consequences. [12]

The ESC advisory service was created to address ESC issues identified at the start of GCGH research projects, as well as challenges encountered as projects progress. [6] An advisory service co-leader and a lead bioethicist are assigned to each GCGH project. During the initial phase of communication, the co-leader and lead bioethicist define the issues and develop a strategy for addressing the challenge's issues based on their specific expertise. A process of consultation with the GCGH program officers has also been implemented to help identify issues within the challenges and its individual projects. The program officers often join the advisory service conference calls and offer expertise and insights that help anticipate ESC concerns.[ citation needed ]

Research program

The goal of the research program is to provide knowledge in order to facilitate the successful adoption of technology by GCGH's targeted communities. With working papers, working groups, global case studies, and demonstration projects on public engagement, research enhances the ESC expertise with respect to specific goals of the Grand Challenges. [13]

Criticism

As is the case with most health initiatives, the GCGH have been subject to a fair degree of criticism.

A very widely circulated critique was published in 2005 in The Lancet . In the column, Anne-Emanuelle Birn, Sc.D., an associate professor of Public Health Sciences at the University of Toronto, described the initiative's role as "weak" for focusing too narrowly on the power of science and neglecting the importance of economic, social, and political factors. She cites the 20th century cultural obsession with technological advancement as one that cannot ignore the need to redistribute economic and social resources within impoverished communities. She suggests that rather than trying to finance, develop and distribute new and existing vaccines, a more sustainable effort might focus on public support for a universal, accessible public health system. She references Goal #4, which involves improved nutrition, as a specific challenge that is shortsighted and "overlooks key distributional questions". She explains that because malnutrition and famine are not the result of technical obstacles, but rather, political and economic ones, technology is not the answer. These issues are not about supply or the lack of nutritional value available in foods, but rather, poor income distribution and market shifts leading to populations unable to afford food. [14]

Laurie Garrett, in her article published in Foreign Affairs , says the main problem in global health was lack of resources but with the input of private players such as Bill and Melinda Gates, there has been a major contribution to pressing health issues such as HIV, Malaria, TB and others. Although these contributions are useful, they also highlight specific diseases which are more high-profile or research that may fascinate the public. The BMGF initiative may have provided funds for improving health care but this is not enough to improve public health, as education and an all-disease health system are needed. [15]

Related Research Articles

<span class="mw-page-title-main">United Nations Foundation</span>

The United Nations Foundation is a charitable organization headquartered in Washington, DC, that supports the United Nations and its activities. It was established in 1998 with a $1 billion gift to the United Nations by philanthropist Ted Turner, who believed the UN was crucial for addressing the world's problems. Originally primarily a grantmaker, the UN Foundation has evolved into a strategic partner to the UN, mobilizing support to advance the Sustainable Development Goals (SDGs), and help the UN address issues such as climate change, global health, gender equality, human rights, data and technology, peace, and humanitarian responses. The UN Foundation's main work occurs through building public-private partnerships, communities, initiatives, campaigns, and alliances to broaden support for the UN and solve global problems. The UN Foundation has helped build awareness and advocate for action on, among others, antimicrobial resistance, regional action on climate change, local implementation of the SDGs, as well as global campaigns such as Nothing But Nets against malaria, the Measles & Rubella Initiative, the Clean Cooking Alliance, Girl Up, Shot@Life, and the Digital Impact Alliance, among others. In March 2020, the UN Foundation was also a key founder of the COVID-19 Solidarity Response Fund on behalf of the World Health Organization (WHO), helping to raise over $200 million USD within the first six weeks to support the global response to the COVID-19 pandemic.

<span class="mw-page-title-main">Bill & Melinda Gates Foundation</span> Private foundation founded by Bill and Melinda Gates

The Bill & Melinda Gates Foundation (BMGF), a merging of the William H. Gates Foundation and the Gates Learning Foundation, is an American private foundation founded by Bill Gates and Melinda French Gates. Based in Seattle, Washington, it was launched in 2000 and is reported as of 2020 to be the second largest charitable foundation in the world, holding $49.8 billion in assets. On his 43rd birthday, Bill Gates gave the foundation $1 billion. The primary stated goals of the foundation are to enhance healthcare and reduce extreme poverty across the world, and to expand educational opportunities and access to information technology in the U.S. Key individuals of the foundation include Bill Gates, Melinda French Gates, Warren Buffett, chief executive officer Mark Suzman, and Michael Larson.

Since October 2018, the Center for Global Infectious Disease Research has been part of the Seattle Children's Research Institute. At the time of the merger, CID Research had 166 scientists. Its mission was to eliminate the world's most devastating infectious diseases through leadership in scientific discovery. The organization's research labs were in the South Lake Union area of Seattle, WA. The institute's research focused on four areas of infectious disease: HIV/AIDS, malaria, tuberculosis (TB), and Emerging & Neglected Diseases (END) like African sleeping sickness, leishmaniasis, Chagas disease, and toxoplasmosis. CID Research was engaged in early stages of the scientific pipeline including bench science and malaria clinical trials and has expertise in immunology, vaccinology, and drug discovery.

<span class="mw-page-title-main">Neglected tropical diseases</span> Diverse group of tropical infectious diseases which are common in developing countries

Neglected tropical diseases (NTDs) are a diverse group of tropical infections that are common in low-income populations in developing regions of Africa, Asia, and the Americas. They are caused by a variety of pathogens, such as viruses, bacteria, protozoa, and parasitic worms (helminths). These diseases are contrasted with the "big three" infectious diseases, which generally receive greater treatment and research funding. In sub-Saharan Africa, the effect of neglected tropical diseases as a group is comparable to that of malaria and tuberculosis. NTD co-infection can also make HIV/AIDS and tuberculosis more deadly.

<span class="mw-page-title-main">PATH (global health organization)</span> Global health nonprofit

PATH is an international, nonprofit global health organization. PATH is based in Seattle with 1,600 employees in more than 70 countries around the world. Its president and CEO is Nikolaj Gilbert, who is also the Managing Director and CEO of Foundations for Appropriate Technologies in Health (FATH), PATH's Swiss subsidiary. PATH focuses on six platforms: vaccines, drugs, diagnostics, devices, system, and service innovations.

<span class="mw-page-title-main">African Malaria Network Trust</span> Non-governmental organization

The African Malaria Network Trust (AMANET) is a pan-African international NGO headquartered in Dar es Salaam, Tanzania. It originally started its activities as African Malaria Vaccine Testing Network (AMVTN) in 1995 with the primary goal of preparing Africa in planning and conducting malaria vaccine trials. In order to widen the scope in malaria interventions, AMVTN was succeeded by AMANET on 14 March 2002. Although the primary goal of AMANET has remained malaria vaccine development, the organization in its expanded role includes other intervention measures such as antimalaria drugs and vector control.

The Center for Infectious Disease Research and Policy (CIDRAP) is a center within the University of Minnesota that focuses on addressing public health preparedness and emerging infectious disease response. It was founded in 2001 by Dr. Michael Osterholm, in order to "prevent illness and death from infectious diseases through epidemiological research and rapid translation of scientific information into real-world practical applications and solutions".

Global Health Initiatives (GHIs) are humanitarian initiatives that raise and disburse additional funds for infectious diseases – such as AIDS, tuberculosis, and malaria – for immunizations and for strengthening health systems in developing countries. GHIs classify a type of global initiative, which is defined as an organized effort integrating the involvement of organizations, individuals, and stakeholders around the world to address a global issue.

The Global HIV Vaccine Enterprise is an alliance of organizations formed to accelerate the search for an HIV vaccine. Initially proposed in Science magazine in 2003 and developed by scientists, health experts and policy makers, the concept of the Enterprise received support from the G8 the following year. The primary aim of the organization is to provide leadership in efforts to reverse the AIDS epidemic. The organization, based in New York City, was founded by representatives from The Gates Foundation, NIH, WHO-UNAIDS, European Commission, Wellcome Trust, International AIDS Vaccine Initiative, French National Agency for Research on AIDS and Viral Hepatitis.

This page is a timeline of global health, including major conferences, interventions, cures, and crises.

Grand Challenges Canada (GCC) is a Canadian nonprofit organization that uses a Grand Challenges model to fund solutions to critical health and development challenges in the developing world.

In global health, priority-setting is a term used for the process and strategy of deciding which health interventions to carry out. Priority-setting can be conducted at the disease level, the overall strategy level, research level, or other levels.

The Malaria Eradication Scientific Alliance (MESA) is an organization founded on the research carried out by the Malaria Eradication Research Agenda (malERA). "malERA" was a project carried out by the scientific community to identify the steps and future research that must be done in order to eradicate malaria. It was created after the Malaria Forum in 2007, hosted by the Bill and Melinda Gates Foundation, reestablished malaria eradication as a long-term goal. "malERA" first launched in 2008, and resulted in a research and development agenda which was published in a PLoS Medicine magazine in 2011. MESA was formed in 2012 to continue the goals of malERA through research and development of methods to fight malaria.

Pedro L. Alonso, is a physician, epidemiologist, and researcher in diseases that affect vulnerable populations. Based on a multidisciplinary approach, his work focuses mainly on malaria, although he has also studied other infectious diseases. He served as the Director of the Global Malaria Programme at the World Health Organization between 2014 and 2022, and is currently Professor of Global Health at the Faculty of Medicine and Health Science-Hospital Clinic, at the University of Barcelona.

Robert Michael Hecht is an American global health policy and financing expert. Hecht is currently Founder and President of Pharos Global Health Advisors. He has previously held positions with the World Bank, UNAIDS, the International AIDS Vaccine Initiative, and Results for Development Institute. He serves as a lecturer at Yale University’s Jackson Institute for Global Affairs and is a clinical professor at the Yale School of Public Health. He has published on a range of topics in global health and development, with a special focus on the economics, financing, and policies for infectious diseases, nutrition, and broader health system reform. He has been an advisor to the President's Emergency Plan for AIDS Relief (PEPFAR), the World Health Organization, and UNITAID. Hecht holds a BA from Yale and a PhD from Cambridge University.

Deepak Gaur was an Indian molecular biologist, and a professor at the School of Biotechnology of Jawaharlal Nehru University. Known for his studies on Plasmodium falciparum, Gaur is a recipient of the N-Bios Prize. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards, for his contributions to medical sciences in 2017.

Francisca Mutapi is a Professor in Global Health Infection and Immunity, co-Director of the Global Health Academy at the University of Edinburgh, and Deputy Director of the National Institute for Health Research (NIHR) Global Health Research Unit Tackling Infections to Benefit Africa. She is the first black woman known to have been awarded a professorship by the University of Edinburgh.

<span class="mw-page-title-main">Nir Eyal (bioethicist)</span>

Nir Eyal is a bioethicist and Henry Rutgers Professor of Bioethics and Director of the Center for Population–Level Bioethics at Rutgers University in New Jersey. He was formerly a bioethicist in the Department of Global Health and Population of the Harvard T.H. Chan School of Public Health and the Department of Global Health and Social Medicine of the Harvard Medical School. He has long worked closely with Harvard bioethicist Daniel Wikler. Eyal's current visibility concerns his role in studying the ethics of human challenge trials in HIV, malaria, and coronavirus vaccine development. He has also written on 'bystander risks' during pandemics and infectious diseases and contract tracing during ebola.

Evelyn Nungari Gitau is a Kenyan cellular immunologist at the African Academy of Sciences, and was named a Next Einstein Fellow.

The European Vaccine Initiative (EVI) is a non-profit Product Development Partnership (PDP) with the goal of supporting and accelerating the development of effective and affordable vaccines for global health. Since its inception in 1998, EVI has operated as an independent non-profit organisation that works closely with academic researchers, the private sector, governments, and other organisations to spearhead vaccine development. Headquartered in Heidelberg, Germany, EVI collaborates with partners across the world to pursue its mission.

References

  1. 1 2 Tindana PO (2007). "Grand Challenges in Global Health: Community Engagement in Research in Developing Countries". PLOS Med. 4 (9): e273. doi:10.1371/journal.pmed.0040273. PMC   1989740 . PMID   17850178.
  2. 1 2 Peter A Singer (2007). "Grand Challenges in Global Health: The Ethical, Social and Cultural Program". PLOS Med. 4 (9): e265. doi:10.1371/journal.pmed.0040265. PMC   1989734 . PMID   17850175.
  3. ↑ "Grand Challenges: Achieving Healthy Growth Grant Opportunity". Archived from the original on 2011-12-25.
  4. ↑ "Grand Challenges in Global Health". Archived from the original on 2013-09-03.
  5. ↑ H. Varmus; R. Klausner; E. Zerhouni; T. Acharya; A. S. Daar; P. A. Singer (2003). "Grand Challenges in Global Health". Science. 302 (5644): 398–399. doi:10.1126/science.1091769. PMC   243493 . PMID   14563993.
  6. 1 2 3 Anant Bhan (2007). "Grand Challenges in Global Health: Engaging Civil Society Organizations in Biomedical Research in Developing Countries". PLOS Med. 4 (9): e272. doi:10.1371/journal.pmed.0040272. PMC   1989739 . PMID   17850177.
  7. ↑ "GHIT Funds Grand Challenges", Asian Scientist Magazine, February 9, 2015 (http://www.asianscientist.com/2015/02/topnews/ghit-funds-grand-challenges/), accessed on 10/20/2015
  8. ↑ "About Grand Challenges". Global Grand Challenges. Retrieved 17 October 2022.{{cite web}}: CS1 maint: url-status (link)
  9. ↑ "Opp1083134".
  10. ↑ "Rewarding Innovative Ideas".
  11. ↑ Singer, P. A.; Taylor, A. D.; Daar, A. S.; Upshur, R. E.; Singh, J. A.; Lavery, J. V. (September 2007). "Grand Challenges in Global Health". PLOS Medicine. 4 (9): e265. doi:10.1371/journal.pmed.0040265. PMC   1989734 . PMID   17850175.
  12. ↑ Berndtson, Kathryn, Tina Daid, C. Shawn Tracy, Anant Bhan, Emma R. M. Cohen, Ross E. G. Upshur, Jerome A. Singh, Abdallah S. Daar, James V. Lavery, and Peter A. Singer (2007). "Grand Challenges in Global Health: Ethical, Social, and Cultural Issues Based on Key Informant Perspectives". PLOS Medicine. 4 (9): e268. doi:10.1371/journal.pmed.0040268. PMC   1989735 . PMID   17850176.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  13. ↑ Singer, Peter A., Andrew D. Taylor, Abdallah S. Daar, Ross E. G. Upshur, Jerome A.Singh, and James V. Lavery (2007). "Grand Challenges in Global Health: The Ethical, Social and Cultural Program". PLOS Medicine. 4 (9): e265. doi:10.1371/journal.pmed.0040265. PMC   1989734 . PMID   17850175.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  14. ↑ Birn, Anne-Emanuelle (2005). "Gates's Grandest Challenge: Transcending Technology as Public Health Ideology". The Lancet. 366 (9484): 514–519. doi:10.1016/S0140-6736(05)66479-3. PMID   16084261. S2CID   19135418.
  15. ↑ Garrett, Laurie (2007). "The Challenge of Global Health". Foreign Affairs. 86 (1): 14–38. JSTOR   20032209.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.